Nkarta Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Nkarta Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
South SAN Francisco
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
NKTX
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001787400
EIN
47-4515206

Board of directors

Follow this board

Chief executives

Paul J. Hastings · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 33 other boards.

Network of Nkarta Inc.'s board connections SpyGlass Pharma Inc. SpyGlass Pharma Inc. Black Diamond Therapeutics Inc. Black Diamond Therapeu... LENZ Therapeutics Inc. LENZ Therapeutics Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... CRISPR Therapeutics AG CRISPR Therapeutics AG Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... Kalaris Therapeutics Inc. Kalaris Therapeutics I... Ali Behbahani Ali Behbahani Leone D. Patterson Leone D. Patterson Michael Dybbs Michael Dybbs Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Simeon George Simeon George Zachary Scheiner Zachary Scheiner Nkarta Inc.
Shared director Other board Same sector +17 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$70,422
3 sales by 2 insiders
Date Insider Transaction Shares Price Value
Jun 18, 2026 Paul J. Hastings Director, Officer (Chief Executive Officer) Open-market sale −1,776 $2.71 $4,813
Jan 15, 2026 Paul J. Hastings Director, Officer (Chief Executive Officer) Open-market sale −26,046 $2.07 $53,915
Jan 15, 2026 Mahmood Nadir Officer (President) Open-market sale −5,649 $2.07 $11,693
Jan 6, 2026 Rose Shawn Marshall Officer (See Remarks) Grant or award +70,000 — —
Jan 6, 2026 Mahmood Nadir Officer (President) Grant or award +80,000 — —
Jan 6, 2026 Paul J. Hastings Director, Officer (Chief Executive Officer) Grant or award +94,000 — —
Jun 18, 2025 Paul J. Hastings Director, Officer (Chief Executive Officer) Open-market sale −1,790 $1.79 $3,204
Jan 15, 2025 Shook David Officer (See Remarks) Open-market sale −8,638 $2.20 $19,004
Jan 15, 2025 Levin Alyssa Officer (See Remarks) Open-market sale −5,838 $2.20 $12,844
Jan 15, 2025 Brandenberger Ralph Officer (Chief Technical Officer) Open-market sale −7,447 $2.20 $16,383
Jan 15, 2025 Paul J. Hastings Director, Officer (Chief Executive Officer) Open-market sale −17,378 $2.20 $38,232
Jan 15, 2025 Hager Alicia J. Officer (Chief Legal Officer) Open-market sale −9,584 $2.20 $21,085
Jan 3, 2025 Shook David Officer (See Remarks) Grant or award +59,000 — —
Jan 3, 2025 Levin Alyssa Officer (See Remarks) Grant or award +52,500 — —
Jan 3, 2025 Brandenberger Ralph Officer (Chief Technical Officer) Grant or award +52,500 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.